RT Journal Article
SR Electronic
T1 Implications of <em>MGMT</em> promoter methylation and its downstream <em>hMSH2</em> mRNA in primary malignant glioma
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 19008763
DO 10.1101/19008763
A1 Manuel, Jeru-Manoj
A1 Narasinga Rao, K V L
A1 Chetan, G K
YR 2019
UL http://medrxiv.org/content/early/2019/10/18/19008763.abstract
AB Background Hypermethylation of 06-methylguanine DNA methyltransferase (MGMT)promoter seen in high grade gliomas (HGG) leads to the accumulation of O6-meG DNA damage which mispairs with thymine, requiring recognition by mismatch repair protein dimer MutSα, whose primary component is coded by Human MutS homolog protein 2 (hMSH2). O6-meG repair necessitates the interaction/combined action of MGMT andhMSH2 to maintain genomic stability. Analysis of the correlation between MGMT methylation and hMSH2mRNAexpression in HGG and their role in the prognosis was explored.Methods Study was performed on 54 primary-frontal lobe HGG tumors, MGMT promoter methylation was detected by Q-MSP and Q-PCR was used to analyse hMSH2 m-RNA expression levels.Results MGMT methylation was seen in 62%patients the mean percentage of methylation (PoM) being (17.62±17.20) %. MGMT PoM≥10% had improved Progression free survival (p=0.015) and ≥8% had better Overall survival (p=0.043), indicating its predictive significance. Over expression of hMSH2 was seen in 50% patients with a median fold change of 2.74 (p=0.021). Univariate analysis of high hMSH2 expression with therapy(CT+RT) showed poor PFS (p=0.002). There was no correlation between MGMT methylation and hMSH2 expression.Conclusion MGMT PoM of ≥10% is a significant prognostic marker. Over expression of hMSH2 is prognostic marker for poor treatment response. Lack of/aberrant correlation between MGMT andhMSH2 could indicate impaired DNA repair of O6-meG in HGG, and this could be one of the factors responsible for both, gliomagenesis and variations in treatment response.Competing Interest StatementThe authors have declared no competing interest.Funding StatementPh.D program of the author Jeru-Manoj Manuel was funded by the University Grants Commission-Maulana Azad National Fellowship (UGC-MANF: No.F1-17.1/2011/MANF-CHR-KAR-2143/ SA-III/Website), New Delhi. This study was funded partly by the above mentioned grants and also by the grant from Department of Science and Technology-Science and Engineering Research Board (DST-SERB), New Delhi (No. SR/SO/HS-233/2012).Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.Not ApplicableThe first author of this manuscript is responsible for the possession of data referred to in the manuscript.HGG(High grade glioma)O-6meG(DNA adduct at O-6 position)MGMT(O-6-Methylguanine DNA methyltransferase)MMR(Mismatch repair genes)hMSH2(human MUTS homolog 2)AOD(Anaplastic oligodendroglioma)AOA(Anaplastic mixed Oligoastrocytoma)AA(Anaplastic astrocytoma)AE(Anaplastic ependymomas)GB(Glioblastoma)PMR(Percentage methylated reference)PoM(Percentage of Methylation)PFS(Progression free survival)OS(Overall survival)CT(Chemotherapy)RT(Radiotherapy)TMZ(Temozolomide)